Adult and childhood acute lymphoblastic leukemia: Clinico-biological differences based on CD34 antigen expression

Haematologica

Volumn 82, Issue 1, 1997, Pages 31-37

  Cascavilla, Nicola ^a   Musto, Pellegrino ^a   D'Arena, Giovanni ^a   Ladogana, Saverio ^a   Matera, Rosella ^a   Carotenuto, Mario ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Acute lymphoblastic leukemia; CD34; Prognostic factors

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; DNA; GLYCOPROTEIN P; HEMOGLOBIN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY KI 67;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATOSPLENOMEGALY; HUMAN; HUMAN CELL; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, NEOPLASM; CELL DIVISION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LIFE TABLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0031467112     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma. Blood 1986; 68:1-31.
2. Pui CH, Behm FG, Crist WM. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82:343-62.
3. De Rossi G, Grossi C, Foa R, et al. Immunophenotype of acute lymphoblastic leukemia cells: the experience of the Italian Cooperative Group (GIMEMA). Leuk Lymphoma 1993; 9:221-8.
4. Reaman G, Zeltzer P, Bleye WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985; 3:1513-21.
5. Baccarani M, Corbelli G, Amadori S, et al. Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Blood 1982; 60:677-84.
6. Della Ragione F, Mercurio C, Iolascon A. Cell cycle regulation and human leukemias: the role of p16INK4 gene inactivation in the development of human acute lymphoblastic leukemia. Haematologica 1995; 80:557-68.
7. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71:123-31.
8. GIMEMA Cooperative Group. Gimema ALL 0183: a multicentric study on adult acute lymphoblastic leukemia. Br J Haematol 1989; 71:377-86.
9. Crist WM, Boyett J, Jackson J, et al. Prognostic importance of the Pre-B cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1989; 74:1252-9.
10. Boucheix C, Bavid B, Sebban C, et al. for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). Blood 1994; 84:1603-12.
11. Hoelzer D. Which factors influence the different outcome of therapy in adults and children with ALL? Bone Marrow Transplant 1989; 4(Suppl 1):98-100.
12. Civin CI, Strauss LC, Brovall C, Falckler MJ, Schwartz JF, Shaper JM. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133:157-65.
13. Watt SM, Karhi K, Gatter K, et al. Distribution and epitope analysis of the cell membrane glycoprotein (HPCA-1) associated with human hemopoietic progenitor cells. Leukemia 1987; 1:417-26.
14. Silvestri F, Banavali S, Baccarani M, Preisler HD. Progenitor cell associated antigen CD34: biology and clinical applications. Haematologica 1992; 77:265-72.
15. Carlo Stella C, Cazzola M, De Fabritiis P, et al. CD34- positive cells: biology and clinical relevance. Haematologica 1995; 80:367-87.
16. Greaves MF. "Target Cells", cellular phenotypes and lineage fidelity in human leukemia. J Cell Physiol 1982; 1(Suppl):113-6.
17. Geller RB, Zanurak M, Hurwitz CA, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (MY10). Br J Haematol 1990; 76:340-7.
18. Borowitz MJ, Gockerman JP, Moor JO, et al. Clinico-pathologic and cytogenic features of CD34 (MY10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 1989; 91:265-70.
19. Campos L, Guyotat D, Archimbaud E, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology, and response to therapy. Br J Haematol 1989; 72:161-6.
20. Cascavilla N, Musto P, Ladogana S, et al. Significato clinico dell'espressione del CD34 nelle leucemie acute. Haematologica 1993; 78(Suppl 1):388-90.
21. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi GL. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymphoma 1994; 13(Suppl 1):81-5.
22. Selleri C, Notar R, Catalano L, Foncana R, Del Vecchio L, Rotoli B. Prognostic irrelevance of CD34 in acute myeloid leukaemia (Letter). Br J Haematol 1992; 82:479-82.
23. Ciolli S, Leoni F, Caporale R, Pascarella A, Salti F, Rossi-Ferrini P. CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica 1993; 78:151-5.
24. Sperling C, Buchner T, Sauerland C, Fonatsch C, Thiel E, Ludwig W. CD34 expression in de novo acute myeloid leukaemia. Br J Haematol 1993; 85:635-7.
25. Del Poeta G, Stasi R, Venditti A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8:388-94.
26. Borowitz MJ, Shuster JJ, Civin CI, et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia. A Pediatric Oncology Group Study. J Clin Oncol 1990; 8:1389-98.
27. Pui CH, Hancock ML, Head DR, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 1993; 3:889-94.
28. Thomas X, Archimbaud E, Charrin C, Magaud JP, Fiere D. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia. Leukemia 1995; 9:249-53.
29. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) Cooperative Group. The morphological classication of acute lymphoblastic leukaemia. Concordance among observers and clinical correlations. Br J Haematol 1981; 47:553-61.
30. Cascavilla N, Greco MM, Ladogana S, et al. Acute myeloid leukemia: correlation between FAB classification criteria and surface antigenie markers. Haematologica 1988; 73:37-42.
31. Musto P, Bavaro P, Cascavilla N, Melillo L, Nobile M. Tecniche immunoenzimatiche di caratterizzazione cellulare: particolari possibilità applicative nella citologia onco-ematologica. Medicina 1987; 7:8-42.
32. Musto P, Matera R, Carotenuto M. Immunocytochemical evaluation of the multidrug resistance phenotype in acute leukemia and multiple myeloma at diagnosis: relevance and relationship to proliferative activity. In: Pieters R, Veerman AJP, Kasper GJL, eds. Drug resistance in leukemia and lymphoma. Advances in blood disorders. London:Harwood Academic Publishers, 1996, in press.
33. Cascavilla N, Musto P, D'Arena G, et al. Are "early" and "late" T-acute lymphoblastic leukemias different diseases? A single center study of 34 patients. Leuk Lymphoma 1996; 21:437-42.
34. Armitage P. Statistical methods in medical research. New York:John Wiley & Sons, 1971.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-81.
36. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39.
37. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc (B) 1972; 34:187-220.
38. Maurer J, Janssen JVG, Thiel E, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337:1055-8.
39. Seeker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age, distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5:196-9.
40. Kraguljac N, Bogdanovic A, Basara N. CD34 antigen expression in adult acute lymphoblastic leukemia. Leukemia 1996; 1:190-1.
41. Miller DR, Leikin S, Albo V. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. Cancer 1983; 51:1041-9.
42. Look AT, Robertson PK, William DL, et al. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 1985; 65:1079-86.
43. Musto P, Cascavilla N, Falcone A, et al. Immunocytochemical evaluation of growth fraction in acute leukemias by means of monoclonal antibody Ki67 [abstract]. Proceedings of the XXII Congress of the International Society of Hematology, Milan, 1988:480.
44. Garand R, Voisin S, Papin S, et al. Characteristics of pro-TALL subgroups: comparison with late-TALL Leukemia 1993; 7:161-7.
45. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994; 97:60-5.
46. Savignano C, Geromin A, Michieli M, et al. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. Haematologica 1993; 78:261-3.
47. Urbano-Ispizua A, Matutes E, Villamor N, et al. Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. Br J Haematol 1990; 75:202-7.
48. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995; 80:280-91.
49. Lerede T, Bassan R, Rossi A, et al. Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. Haematologica 1996; 81:442-9.
50. Vaughan WP, Civin CI, Weisenburger DD, et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia 1988; 2:661-6.